Percentage of Biopsy Cores Positive for Malignancy and Biochemical Failure Following Prostate Cancer Radiotherapy in 3,264 Men: Statistical Significance Without Predictive Performance

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 4, 2008, Pages 1169-1175

  Williams, Scott G ^a   Buyyounouski, Mark K ^b   Pickles, Tom ^c   Kestin, Larry ^d   Martinez, Alvaro ^d   Hanlon, Alexandra L ^b   Duchesne, Gillian M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FOX CHASE CANCER CENTER   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Biochemical failure; Prognostic models; Prostate cancer; Radiotherapy

Indexed keywords

ANTIGENS; BIOPSY; HEALTH RISKS; MODEL PREDICTIVE CONTROL; ONCOLOGY; STATISTICAL METHODS; TUMORS;

BIOCHEMICAL FAILURE; PROGNOSTIC MODELS; PROSTATE CANCER;

RADIOTHERAPY;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR BIOPSY;

AGED; ANDROGEN ANTAGONISTS; BIOPSY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 39749128640     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.08.021     Document Type: Article

References (33)

1. Williams S.G., Duchesne G.M., Gogna N.K., et al. An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. Int J Radiat Oncol Biol Phys 65 (2006) 351-357
2. Williams S.G., Millar J.L., Dally M.J., et al. What defines intermediate-risk prostate cancer? Variability in published prognostic models. Int J Radiat Oncol Biol Phys 58 (2004) 11-18
3. D'Amico A.V., Keshaviah A., Manola J., et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 581-587
4. D'Amico A.V., Schultz D., Silver B., et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49 (2001) 679-684
5. Kestin L.L., Goldstein N.S., Vicini F.A., et al. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 168 (2002) 1994-1999
6. Buyyounouski MK, Hanlon AL, Horwitz EM, et al. The percentage of positive cores is not an appropriate risk factor for prostate radiotherapy to ≥72 Gy [abstract]. Presented at the American Society for Therapeutic Radiology and Oncology 47th Annual Meeting; October 16-20 2005; Denver, CO.
7. Pepe M.S., Janes H., Longton G., et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159 (2004) 882-890
8. Greenland P., and O'Malley P.G. When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 165 (2005) 2454-2456
9. Kattan M.W. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95 (2003) 634-635
10. Simon R. Evaluating prognostic factor studies. In: Gospodarowicz M. (Ed). Prognostic factors in cancer (2001), Wiley-Liss, New York 49-56
11. Ware J.H. The limitations of risk factors as prognostic tools. N Engl J Med 355 (2006) 2615-2617
12. Pickles T., Kim-Sing C., Morris W.J., et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57 (2003) 11-18
13. Buyyounouski M.K., Hanlon A.L., Eisenberg D.F., et al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1455-1462
14. Kestin L.L., Vicini F.A., and Martinez A.A. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 53 (2002) 304-315
15. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
16. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
17. Bahnson R.R., Hanks G.E., Huben R.P., et al. NCCN practice guidelines for prostate cancer. Oncology (Williston Park) 14 (2000) 111-119
18. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
19. Kattan M.W. Evaluating a new marker's predictive contribution. Clin Cancer Res 10 (2004) 822-824
20. D'Amico A.V., Renshaw A.A., Cote K., et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol 22 (2004) 3726-3732
21. Wong W.W., Schild S.E., Vora S.A., et al. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 24-29
22. Merrick G.S., Butler W.M., Wallner K.E., et al. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation. Cancer J 10 (2004) 54-60
23. Papagikos M.A., Rossi P.J., Urbanic J.J., et al. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol 30 (2007) 199-204
24. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
25. Freedland S.J., Aronson W.J., Terris M.K., et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: Results from SEARCH database. J Urol 169 (2003) 2136-2141
26. Freedland S.J., Csathy G.S., Dorey F., et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 167 2 Pt. 1 (2002) 516-520
27. Freedland S.J., Terris M.K., Csathy G.S., et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 171 6 Pt. 1 (2004) 2215-2220
28. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715-717
29. Assmann S.F., Pocock S.J., Enos L.E., et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355 (2000) 1064-1069
30. Royston P., and Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 23 (2004) 2509-2525
31. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
32. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
33. Kattan M.W., Shariat S.F., Andrews B., et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 21 (2003) 3573-3579